Clinical Trials
11 trialsNCT03936959 2025-01-15
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT01394016 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02407990 2021-11-17
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
Phase 1 Completed
NCT00881569 2020-09-28
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
Daiichi Sankyo
Phase 1 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01287520 2019-02-25
A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01394003 2019-01-18
A Study of LY2584702 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT01296568 2019-01-07
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01347866 2018-10-29
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Pfizer
Phase 1 Terminated
NCT01576406 2018-10-25
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Pfizer
Phase 1 Completed
NCT00729833 2014-06-09
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated